Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US.
May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country.
She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate patients and she will support the launch of new products in the US.
May said: “I have been privileged to work in the rare disease field, leading commercial teams in providing education to patients, caregivers and physicians around important rare disease issues.
“I look forward to applying my expertise to help Sobi bring its existing and future products to patients who need them.”
May has had more than 20 years’ experience in biopharmaceutical sales and marketing, with her most recent role serving as head of US marketing for Fabry disease and lysosmal storage disorders at Sanofi Genzyme.
Prior to her 17-year career at Sanofi, May held various sales positions at DuPont Pharmaceuticals and Endo.
Rami Levin, president of Sobi, North America, said: “As we look to increase our footprint specifically in North America, where more than 33 million patients are estimated to suffer from a rare disease, Holly’s experience will be incredibly valuable.”